Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human nerve growth factor for neurotrophic keratitis
ChiCTR2100053592Phase 4Recruiting
- Sponsor
- Xi'an First Hospital
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cenegermin in neurotrophic keratitis (NK), sponsored by Xi'an First Hospital. Primary endpoints: Corneal nerve fiber density and Corneal perception. Started Dec 2021; status: recruiting.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on ChiCTR2100053592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053592.